ASLAN Pharmaceuticals Lim... (ASLN)
0.60
-0.10 (-14.27%)
At close: Jul 18, 2024, 8:00 PM
0.56
-6.67%
After-hours: Jul 18, 2024, 07:58 PM EDT
Company Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.
It has a joint venture with JAGUAHR Therapeutics Pte.
Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway.
Its partners include Almirall, Array BioPharma, and CSL Limited.
The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited
| Country | SG |
| IPO Date | May 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. |
Contact Details
Address: 83 Clemenceau Avenue Singapore, SG | |
| Website | https://aslanpharma.com |
Stock Details
| Ticker Symbol | ASLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001722926 |
| CUSIP Number | 04522R101 |
| ISIN Number | US04522R2004 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, Chief Executive Officer & Executive Director |
| Kiran Kumar Asarpota | Chief Operating Officer & Head of Finance |
| Ben Goodger | General Counsel |
| Charlie Hsu | Investor Relations Director |
| Chi-Chin Wang | IR & Corporate Development Director |
| Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer |
| Stephen Doyle | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 06, 2024 | 25-NSE | Filing |
| Aug 08, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 17, 2024 | 6-K | Filing |
| Jul 15, 2024 | 6-K | Filing |
| Jun 14, 2024 | 6-K | Filing |
| Jun 14, 2024 | F-6 POS | Filing |
| Jun 12, 2024 | F-3 | Filing |
| May 31, 2024 | 6-K | Filing |